Wakefield, MA–In response to a warning letter from the FDA stating that Curaleaf Hemp was “illegally selling unapproved products containing cannabidiol (CBD) online with unsubstantiated claims that the products treat cancer, Alzheimer’s disease, opioid withdrawal, pain and pet anxiety, among other conditions or diseases,” Curaleaf Holdings announced that it been conducting an extensive review of its website and social media platforms to remove all statements that FDA identified as non-compliant.
This includes, according to the announcement, removal of the Curaleaf Hemp blog and the third-party links in the blog, as well as removal of statements and social media posts flagged by the FDA in the warning letter. Curaleaf Hemp also informed the FDA that a number of the products mentioned in the FDA letter had previously been discontinued. Curaleaf Hemp said that the company will “continue to work diligently to ensure that information it provides to consumers on its website and social media platforms are fully compliant with FDA requirements.”
Related: FDA Warns CBD Company Over Unapproved New and Misbranded Drug Products
FTC/FDA Warning Letters Issued to CBD Companies
“Our industry needs, wants and appreciates the work the FDA is doing to ensure there is regulation and compliance in the CBD marketplace,” said Joseph Lusardi, CEO of Curaleaf. “We care deeply about our customers and making a difference in our industry. Curaleaf is committed to being an ethical and responsible company and working with the FDA to be a leader in our industry, setting the standards and guidelines to best service our customers and the communities we serve.”